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1,3-Butadiene (BD) is an important industrial chemical that is
classified as a human carcinogen. BD carcinogenicity has been
attributed to its metabolism to several reactive epoxide metabolites
and formation of the highly mutagenic 1,2:3,4-diepoxybutane
(DEB) has been hypothesized to drive mutagenesis and carcino-
genesis at exposures experienced in humans. We report herein the
formation of DEB-specific N,N-(2,3-dihydroxy-1,4-butadiyl)valine
(pyr-Val) in BD-exposed workers as a biomarker of DEB formation.
pyr-Val was determined in BD monomer and polymer plant
workers that had been previously analyzed for several other
biomarkers of exposure and effect. pyr-Val was detected in 68 of 81
(84%) samples ranging from 0.08 to 0.86 pmol/g globin. Surpris-
ingly, pyr-Val was observed in 19 of 23 administrative control
subjects not known to be exposed to BD, suggesting exposure from
environmental sources of BD. The mean ± SD amounts of pyr-Val
were 0.11 ± 0.07, 0.16 ± 0.12, and 0.29 ± 0.20 pmol/g globin in the
controls, monomer, and polymer workers, respectively, clearly
demonstrating formation of DEB in humans. The amounts of pyr-
Val found in this study suggest that humans are much less efficient
in the formation of DEB than mice or rats at similar exposures.
Formation of pyr-Val was more than 50-fold lower than has been
associated with increased mutagenesis in rodents. The results
further suggest that formation of DEB relative to other epoxides is
significantly different in the highest exposed polymer workers
compared with controls and BD monomer workers. Whether this is
due to saturation of metabolic formation or increased GST-
mediated detoxification could not be determined.
Key Words: biomonitoring; exposure response; risk assessment;
exposure assessment; 1,3-butadiene; globin adducts.
1,3-Butadiene (BD) is an important industrial chemical
heavily used in the production of synthetic rubber and resins
(Himmelstein et al., 1997), and a byproduct of incomplete
combustion found in cigarette smoke, auto exhaust, and fossil
fuels (Agency for Toxic Substances and Disease Registry
[ATSDR], 1992). BD has been recently rated the cigarette
constituent with the highest cancer risk index (Fowles and
Dybing, 2003). Most agencies have classified BD as a human
carcinogen based on evidence from epidemiology and animal
studies (ATSDR, 1992; International Agency for Research on
Cancer [IARC], 2008; National Toxicology Program, 2005;
U.S. EPA Office for Research and Development, and National
Center for Environmental Assessment, 2002). The 2008 IARC
Working Group categorized BD as ‘‘carcinogenic to humans’’
(group 1), on the basis of ‘‘sufficient evidence’’ in humans of
an increased risk for leukemia (IARC, 2008).
BD requires metabolic activation to several epoxide metab-
olites that are known to bind to DNA and proteins.
Subsequently, the mode of action is assumed to be that of
a DNA-reactive compound, and the corresponding key events
have been outlined by Preston (2007), based on the U.S. EPA
guidelines for cancer risk assessment. Formation of promuta-
genic DNA adducts leading to mutations represents the causal
link between exposure and tumor development (Kirman et al.,
2010; Preston, 2007). In rodent cancer studies, BD has been
shown to be a multisite carcinogen in both rats and mice, with
vastly different cancer potencies in the two species. In mice,
tumors arise at exposure concentrations as low as 13.8 mg/m3
(6.25 ppm), whereas in rats, the tumor inducing concentrations
have been at 1000 ppm and higher, although lower exposures
have not been evaluated. This species difference in tumorigen-
esis has been attributed to differences in BD metabolism.
BD is metabolized primarily by P450 2E1 to 1,2-epoxybutene
(EB), 1,2:3,4-diepoxybutane (DEB), and 3,4-epoxy-1,2-butane-
diol (EB-diol) that produce various hemoglobin adducts shown
in Figure 1 (Himmelstein et al., 1997). EB produces N-(2-
hydroxy-3-buten-1-yl)-valine (HB-Val) and DEB forms N,
N-(2,3-dihydroxy-1,4-butadiyl)-valine (pyr-Val) and 2,3,4-
trihydroxybutyl-valine (THB-Val). The later adduct is primarily
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formed from EB-diol and is present in unexposed animals and
humans from endogenous sources (Koc et al., 1999). BD-
derived epoxides differ in their mutagenic potency up to 200-
fold, with DEB being the most mutagenic metabolite (Meng
et al., 2007; Walker et al., 2009). Therefore, to improve the
scientific basis of BD risk assessment, it is important to have
detailed knowledge of the internal formation of each potentially
mutagenic metabolite and its dependence on species, gender,
and exposure concentrations.
THB-Val and HB-Val adducts can be readily measured
using the modified Edman degradation followed by liquid-
liquid extraction and analysis by gas chromatography-mass
spectrometry (GC-MS) or GC-MS/MS (Booth et al., 2004;
Powley et al., 2005; Törnqvist et al., 1986). Unfortunately, the
presence of a tertiary amine makes pyr-Val unsuitable for
analysis by Edman degradation. Therefore, a proteomics
approach using trypsin digestion was established for the
analysis of pyr-Val in rodents (Boysen et al., 2004; Kautiainen
et al., 2000). Utilizing this methodology, Georgieva et al.
recently reported a comprehensive exposure-response on the
formation of DEB-specific pyr-Val adducts in mice and rats
(Georgieva et al., 2010). The formation of DEB was shown to
be much less prominent in rats than mice, with only 10% of the
murine DEB formed in similarly exposed rats (Georgieva et al.,
2010). This is in agreement with greater formation of EB-
derived HB-Val and EB-diol-derived THB-Val adducts in mice
compared with rats exposed similarly (Boysen et al., 2007).
The formation of DEB correlated well with BD-induced
mutation frequencies in the hypoxanthine guanine phosphor-
ibosyl transferase (HRPT) gene of rodents, suggesting that
DEB is the ultimate carcinogenic metabolite at the exposures
studied (Georgieva et al., 2010).
In parallel, studies in BD-exposed workers were conducted
to correlate biomarkers of exposure with biomarkers of effect,
utilizing HB-Val and THB-Val as biomarkers for BD exposure
and metabolism (Albertini et al., 2003; Swenberg et al., 2008,
2011; Vacek et al., 2010 [recently reviewed by Albertini et al.
(2010)]). Results have been fairly consistent regarding
hemoglobin adducts and urinary metabolites, both of which
have been found to be useful biomarkers of exposure and
probes for identifying underlying metabolic pathways. However,
results have been conflicting as to the induction of mutational
events in reporter genes of lymphocytes of occupationally
exposed workers or the importance of genotypes in conferring
FIG. 1. Overview of BD metabolism and formation of N-terminal valine adducts and urine metabolites.
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susceptibility to these events (Albertini et al., 2003). Notewor-
thily, at that time, there were no biomarkers available to measure
production of the highly mutagenic DEB in humans. However,
since then, an assay for quantitation of the DEB-specific pyr-Val
has been developed, validated, and successfully applied to mice
and rats exposed to various concentrations of BD (Boysen et al.,
2004; Georgieva et al., 2010). We report herein the extension of
this methodology to humans and demonstrate for the first time
the presence of pyr-Val in BD-exposed workers.
Cryopreserved red blood cells were available from male
workers in monomer production and polymerization facilities in
the Czech Republic (Albertini et al., 2003). The study included
extensive external exposure assessments, with individual worker
measurements being made by personal monitors over 8-h work
shifts on an average of 10 workdays over several months
preceding biological sample acquisitions (Albertini et al., 2003).
Specimens had previously been analyzed for protein adducts
(HB-Val and THB-Val), urinary biomarkers, mutation in HPRT
gene, and chromosome aberrations (Albertini et al., 2003). Urine
metabolites and hemoglobin adducts (HB-Val and THB-Val)
were both highly correlated with external exposure concen-
trations, with protein adducts being the best-correlated bio-
markers of exposure. In addition to serving as internal
dosimeters, these biomarkers also reflected BD metabolic
pathways in these workers. In contrast, biomarkers of effect
did not show increases in frequencies of gene mutations,
measured at the HPRT locus in blood lymphocytes, or of
chromosome aberrations, measured by a variety of methods.
These biomarker studies were blinded as to BD exposures until
data were final. Of the many genotypes evaluated, only that for
GST showed an effect, which modulated the relative amounts of
the two urinary metabolites.
MATERIALS AND METHODS
Trypsin (biotin-agarose, from bovine pancreas) was purchased from Sigma-
Aldrich (St Louis, MO). All reagents and solvents were ACS grade or higher.
Centricon 3 filters were obtained from Amicon Inc. (Beverly, MA) and
Microspin filter tubes (regenerated cellulose, 0.2 lm) were from Alltech
Associates Inc. (Deerfield, IL). Polyclonal antibodies against pyr-Val (1–11)
were raised by AnaSpec (San Jose, CA) using a standard peptide synthesized as
described previously (Jayaraj et al., 2003).
Human subjects. Eighty-three subjects were studied for biomarkers of
exposures and effect. Of these, 23 were controls (administrative workers), 24
were BD monomer production workers, and 34 were BD polymer production
workers (Table 1). Details of the study population have been reported
previously (Albertini et al., 2003). The experimental protocol was approved by
the Institutional Review Boards at Regional Institute of Hygiene of Central
Bohemia, the University of Vermont, and the University of North Carolina at
Chapel Hill. Red blood cells were isolated, washed twice with 0.9% saline,
diluted 2 3 in distilled water, and stored at 80C before extraction of globin.
Exposure assessment. BD exposures were determined by personal
monitoring tubes for 8-h work shifts on 10 separate occasions over a 4-month
interval for each study subject. Ambient air samples were also analyzed for BD
concentrations. Coexposures to toluene, styrene, and benzene were measured
by personal monitoring in a subset of subjects on a single occasion and by
ambient air sampling (Albertini et al., 2003).
Quantitation of pyr-Val. Amounts of pyr-Val were measured based on
a procedure described by Boysen et al. (2004) using peptide standards that had
been quantified accurately as described by Bordeerat et al. (2009). In brief,
globin isolation was performed according to Mowrer et al. (1986). Globin
samples of 50 mg were dissolved in 1.5 ml of 0.1M NH4HCO3, and 2 pmol of
internal standard [2H3]N,N-(2,3-dihydroxy-1,4-butadyil)-valine (1–11) peptide
was added. Samples were digested for 24 h at 37C with 100 ll of trypsin-
biotin-agarose suspension (washed in advance twice with 0.1M NH4HCO3).
After Centricon 3 filtration, samples were dried and redissolved in 600 ll PBS
buffer, loaded on immunoaffinity (IA) columns, and left capped for 1 h. After
extensive washing with distilled water (5 3 7 ml) and elution in 3 ml of 5%
formic acid, followed by sample drying, filtration on Microspin filters, and final
drying, samples were stored at 20C until analysis by nano-ultra high
pressure liquid chromatography tandem mass spectrometry (UPLC-MS/MS).
Liquid chromatography and mass spectrometry. The quantitative anal-
ysis of the pyr-Val and [2H3]pyr-Val by nano-UPLC-MS/MS was performed
with an nano-UPLC (Waters, Milford, MA) coupled to a TSQ-Quantum Ultra
Triple Quad Mass Analyzer (ThermoFinnigan, San Jose, CA). The system
utilized a 2.0 3 20 mm Symmetry C18, 5 lm column (Waters) as ‘‘trap
column’’ for samples loading at 15 ll/min 15 mM ammonium formate-0.7%
formic acid. After sample loading, the flow rate was reduced to 1.2 ll/min, and
the column exit flow was directed to an ‘‘analytical column’’ consisting of
a 100 lm 3 100 mm BEH C18 UPLC column (Waters). pyr-Val and
[2H3]-pyr-Val were eluted with a linear gradient of 5% 15mM ammonium
formate-0.7% formic acid, for 2 min then to 70% acetonitrile-0.1% formic acid,
in 10 min, at a flow rate of 1.2 ll/min. The retention times for the analyte and
internal standard were determined with authentic standards. pyr-Val and
[2H3]pyr-Val were detected in selected reaction monitoring mode, monitoring
TABLE 1
Hemoglobin Adducts (pmol/g) by Group
BD exposure HB-Val pyr-Val THB-Val
Relative Adduct Amounts (%)
mg/m3 (ppm) Mean ± SD Mean ± SD Mean ± SD HB-Val pyr-Val THB-Val
Controls (n ¼ 23) 0.023 (0.01) 0.22 ± 0.20 0.11 ± 0.07 95.0 ± 38.7 0.26 0.13 99.61
Monomer (n ¼ 24) 0.64 (0.29) 0.47 ± 0.45 0.16 ± 0.12 179 ± 101a 0.26 0.11 99.63
Polymerization (n ¼ 34) 1.79 (0.81) 2.23 ± 1.40 0.29 ± 0.20a,b 716 ± 426a,b 0.33a 0.05a,b 99.62
aSignificantly different from controls; p < 0.05 by K-W test.
bSignificantly different from monomer production workers; p < 0.05 by K-W test.
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the transitions of the double charged ions to the a1-fragment (m/z 417.25 to
158.25 and m/z 418.75 to 158.75, for analyte and internal standard,
respectively). The electrospray conditions were: spray voltage of 1800 V and
capillary temperature of 240C. Collision energy was 28 V.
Statistical analysis. The three groups (control, monomer and polymer
workers) were compared using the nonparametric Kruskal-Wallis (K-W) test.
Pairwise differences were assessed by Mann-Whitney tests using a Bonferroni
adjustment for multiple comparisons. Two-way Spearman’s rank correlation
coefficients were computed to assess bivariate associations of pyr-Val with BD
exposure measurements and biomarkers of exposure and effect. These
nonparametric analyses are robust because they rely on fewer assumptions
about the data distributions and are less influenced by outliers than parametric
analyses. However, BD exposures, hemoglobin adducts, and urine metabolites
appear to be log-normally distributed, so Pearson correlation coefficients were
also computed to assess the linearity of their bivariate relationships after
logarithmic transformation of the exposure measurements and biomarkers.
Multiple regression was used to examine whether the linear relationships
differed between metabolic genotypes. These regression analyses included an
interaction term to test whether the rate of increase in the biomarker per unit of
exposure was modified by genotype. Two-way ANOVA was used to test for
interactions between the effects of genotype and exposure group.
RESULTS
The previously established capillary liquid chromatography
LC-MS/MS method for mice and rats was extended and
validated for analyses of human globin. Therefore, globin from
a volunteer with no detectable amounts of pyr-Val was spiked
with various amounts of synthetic human pyr-Val (1–11)
peptide standard. It was previously reported and herein
confirmed that the anti-pyr-Val antibody used for preparation
of the IA columns retains pyr-Val from mice, rats, and humans
with equal affinity because of the sequence similarity at the
N-terminus (Boysen et al., 2004, 2007). The final quantitative
analysis was performed with nano-UPLC-MS/MS instead of
the reported capillary LC-MS/MS to increase sensitivity by 10-
fold. Analysis of control globin spiked with synthetic pyr-Val
(1-11) peptide standards before and in parallel with the human
globin samples confirmed recoveries of > 97% and precision of
> 90% (Fig. 2). Of the 83 subjects, 68 (84%) had quantifiable
amounts of pyr-Val ranging from 0.02 to 0.86 pmol/g.
A representative ion chromatogram is shown in Figure 3,
demonstrating the presence of pyr-Val in humans.
pyr-Val Concentrations Versus BD Exposures
BD exposures in the three worker groups studied, summarized
as group mean 8-h TWA concentrations in air measured by
personal monitors, were 0.023 mg/m3 (0.01 ppm), 0.64 mg/m3
(0.29 ppm), and 1.79 mg/m3 (0.81 ppm) for the controls,
monomer production workers, and polymerization workers,
respectively. The corresponding mean pyr-Val adduct concen-
trations were 0.11 ± 0.07, 0.16 ± 0.12, and 0.29 ± 0.20 pmol/g
globin for the 23 controls, 24 monomer production workers, and
35 polymerization workers, respectively (Table 1). The value of
0.29 pmol/g globin for the polymerization workers was
significantly greater than the values for the controls or monomer
workers (p < 0.05; K-W test). The adduct concentrations for the
latter two groups did not differ significantly from each other.
There was a significant correlation between pyr-Val concen-
trations and average BD exposures of individual workers,
measured as the mean of each worker’s 10 separate semi-random
determinations, when all groups were combined (rho ¼ 0.40,
p < 0.001, Fig. 4). There were no significant correlations within
either the monomer (rho ¼ 0.24, p ¼ 0.253) or polymerization
worker group (rho ¼ 0.05, p < 0.779) when these workers were
analyzed separately, even though BD exposures within these
groups varied widely (Fig. 4).
pyr-Val Concentrations Versus HB-Val and THB-Val
Concentrations
The pyr-Val concentrations were compared with the pre-
viously determined concentrations of HB-Val, reflecting EB
levels, and THB-Val, reflecting EB-diol levels, in these
workers at the time of study. Group mean ± SD HB-Val
concentrations were 0.22 ± 0.21, 0.47 ± 0.45, and 2.23 ± 1.40
pmol/g globin for the controls, monomer production workers,
and polymerization workers, respectively, whereas the corre-
sponding THB-Val concentrations were 94.77 ± 38.71, 178.73
± 101.31, and 716.70 ± 425.72, respectively (Table 1). As
reported earlier, the mean concentrations of both HB-Val and
THB-Val were significantly higher in the monomer production
workers than the controls and in the polymerization workers
than in either the controls or monomer production workers (p <
0.05; K-W test). Similarly, both the HB-Val and THB-Val
concentrations were significantly correlated with worker
average BD exposure levels, measured as the mean of each
worker’s multiple separate measurements, when all groups
FIG. 2. Validation curve for detection of pyr-Val in human globin.
Human globin from a volunteer that had no detectable amounts of pyr-Val was
spiked with various amounts of synthetic pyr-Val standard peptide (1–11) and
analyzed as describe in ‘‘Materials and Methods.’’ Shown are the positive
controls containing 5–100 fmol/samples representing 0.1–2 fmol pyr-Val/g
globin. The insert shows extended positive controls containing up to 350 fmol
pyr-Val/sample.
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were combined (rho ¼ 0.676, p < 0.001 for HB-Val and rho ¼
0.737, p < 0.001 for THB-Val). These correlations remained
significant within the monomer production and polymerization
worker groups for both adducts. The reported values for HB-
Val and THB-Val represent the total of both a- and b-chains,
whereas pyr-Val is the amount on the a-chain.
The percentages of the three adducts were computed for each
worker and the means for the controls, monomer workers, and
polymerization workers are shown in Table 1. For all groups,
the mean percent of THB-Val was 99.6%, indicating the
dominance of EB-diol formation compared with formation of
EB and DEB. The mean percent of HB-Val was 0.26% in both
the controls and the monomer workers, about double that of
pyr-Val (0.13% and 0.11%, respectively). In the polymeriza-
tion workers, the mean percent of HB-Val increased to 0.33%,
whereas the mean percent of pyr-Val decreased to 0.05%. The
decrease in pyr-Val was significantly related to increasing BD
exposure levels (rho ¼ 0.404, p ¼ 0.002), but there was no
significant correlation between BD exposure and either the
percent of HB-Val (rho ¼ 0.106, p ¼ 0.428) or THB-Val (rho
¼ 0.101, p ¼ 0.449). The pyr-Val concentrations in individual
workers were significantly correlated with their HB-Val
concentrations when the analysis included all subjects
combined (rho ¼ 0.59, p < 0.001) and for both the monomer
production workers (rho ¼ 0.48, p < 0.05) and the
polymerization workers (rho ¼ 0.30, p < 0.05) when workers
in these two groups were analyzed separately (Table 2, Fig. 5).
pyr-Val concentrations were also significantly correlated with
the THB-Val concentrations of individual workers when all
subjects were included (rho ¼ 0.60, p < 0.001), but this
significant correlation was seen only within the polymerization
group (rho ¼ 0.051, p < 0.001) when the groups were analyzed
separately (Table 2, Fig. 6).
pyr-Val Concentrations Versus Urinary Metabolites
The amounts of pyr-Val were further compared with pre-
viously determined concentrations of urinary metabolites in these
workers (Table 3) (Albertini et al., 2003). After work group mean
± SD concentrations of the M1 metabolite (1,2-dihydroxy-4[N-
acetylcysteinyl]-butane), reflecting the EH-mediated hydrolysis
detoxification pathway, were 353 ± 157, 764 ± 728, and 4647 ±
6630 lg/l for the controls, monomer production, and polymer-
ization workers, respectively. For the M2 metabolite (isomeric
mixture of 1-hydroxy-1-[N-acetylcysteinyl]-3-butene and
2-hydroxy-1-[N-acetylcysteinyl]-3-butene), reflecting the GST-
mediated conjugation detoxification pathway, these group mean
± SD after work concentrations were 1.70 ± 1.54, 9.44 ± 12.97,
and 120.17 ± 228.17 lg/l for the three worker groups,
respectively. The mean urine concentrations of both metabolites
were significantly higher in polymerization workers than in
control and monomer production workers. In the monomer
production workers, these concentrations were significantly
FIG. 3. Representative ion-chromatogram of pyr-Val from BD-exposed
subject. Globin was isolated and analyzed for presence of pyr-Val by
immunoaffinity nano-UPLC-MS/MS as described in ‘‘Materials and Meth-
ods.’’ The sample shown is from a monomer worker exposed to 3.7 mg/m3 (1.6
ppm) BD TWA and had 0.23 pmol pyr-Val per g globin.
FIG. 4. Associations between individual pyr-Val hemoglobin adduct
concentrations (ln[pmol/g]) and 4-month average BD exposure (ln[mg/m3]).
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higher than in the controls. As reflected in the ratio M1/(M1 þ
M2), the hydrolysis pathway dominated BD metabolism in these
workers, similar to what was reflected by the hemoglobin
adducts; the ratios being 0.995, 0.988, and 0.975 for the mean
urine metabolite values in the three worker groups, respectively
(Table 3). The inverse ratios (M2/[M1 þ M2]), reflecting the
minor conjugation detoxification pathway, were 0.005, 0.012,
and 0.025 in the controls, monomer production workers, and
polymerization workers, respectively, suggesting that this
pathway was enhanced in the polymer workers (Table 3).
Analysis of these ratios by genotype indicated that GST-mediated
conjugation of BD metabolites was reduced by both the GST M1
and the GST T1 null genotypes compared with the respective
positive genotypes, and this reduction was statistically significant
for the GST M1 null workers (data not shown). Both the M1 and
the M2 urinary metabolites were significantly correlated with BD
exposures of the individual workers, determined as the mean of
each worker’s multiple independent exposure measurements, and
with both the HB-Val and THB-Val hemoglobin adduct
concentrations, when the analysis included all subjects (data
previously published and not shown here [Vacek et al., 2010]).
These significant correlations persisted when the analysis was
within the monomer production or polymerization exposure
groups alone (data previously published and not shown (Vacek
et al., 2010).
Table 4 and Figures 7–9 show that the pyr-Val concen-
trations for individual workers were significantly correlated
with both the urine M1 and the M2 concentrations, and with
the ratio M2/(M1 þ M2), when the analysis included all
workers in all three groups. However, when worker groups
were analyzed separately, only the correlation between pyr-Val
and urine M1 concentrations in monomer production workers
remained significant (Table 4).
pyr-Val Concentrations and HPRT Mutations
HPRT mutations were measured previously by both cloning
assays and autoradiography (Albertini et al., 2003). There were
no significant differences in group mean mutant frequencies (MF
determined by cloning) or variant frequencies (VF determined
by autoradiography) between the worker groups. Similarly, there
were no significant correlations between MFs or VFs and urine
metabolites or hemoglobin adducts. For neither of the HPRT
mutation assays were the values influenced by worker genotype.
TABLE 2
Czech 1 Study: Spearman Correlations Between
Hemoglobin Adducts
Correlation with pyr-Val
Control Monomer Polymerization All
HB-Val 0.10 0.48* 0.36* 0.59**
THB-Val 0.36 0.25 0.51** 0.60**
*p < 0.05, **p < 0.01.
FIG. 5. Associations between individual pyr-Val hemoglobin adduct
concentrations (ln[pmol/g]) and HB-Val hemoglobin adducts (ln[pmol/g]).
FIG. 6. Associations between individual pyr-Val hemoglobin adduct




Metabolite Mean ± SD Mean ± SD Mean ± SD
M1 353 ± 157 764 ± 728a 4647 ± 6.63a,b
M2 1.70 ± 1.54 9.44 ± 12.97a 120.2 ± 228.2a,b
M1/(M1 þ M2) 0.995 ± 0.004 0.988 ± 0.11a 0.975 ± 0.967a
M2/(M1 þ M2) 0.005 ± 0.004 0.012 ± 0.11a 0.025 ± 0.967a
aSignificantly different from controls; p < 0.05 by K-W test.
bSignificantly different from monomer production workers; p < 0.05 by K-W
test.
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Similar to the correlations with other biomarkers in this
study, amounts of pyr-Val from individual workers were
unrelated to either MFs (rho ¼ 0.18, p ¼ 0.117) or VFs (rho ¼
0.26, p ¼ 0.67) when the analysis included all workers in the
study. The correlations remained nonsignificant when analysis
was limited to each worker group (data not shown).
pyr-Val Concentrations and Chromosome Aberrations
Chromosome aberrations were determined previously by
conventional analysis and by fluorescent in situ hybridization
(FISH) (Albertini et al., 2003). Two endpoints were measured
using conventional techniques, and eight were determined by
FISH. In addition, sister chromatid exchanges were measured.
Table 5 shows that, when data from all workers were included
in the analysis, a significant negative correlation was observed
between the number of chromosome breaks per cell determined
by conventional techniques and individual worker pyr-Val
amounts (rho ¼ 0.22, p < 0.05). This correlation was not seen,
however, when the worker groups were analyzed separately.
There were no significant correlations between pyr-Val and any
of the multiple endpoints determined by FISH (Table 5).
However, when analysis was limited to workers within the
monomer production worker group, there were significant
negative correlations between all FISH endpoints and pyr-Val
(Table 5). These significant negative relationships were not
seen for the controls or polymerization workers. It is difficult to
ascribe these findings to real DEB effects, as evidenced by pyr-
Val, on chromosomal changes, given the large number of
comparisons made in these analyses.
pyr-Val Concentrations and Worker Genotypes
Several metabolic genotypes were reported previously for
the subjects in this first Czech study (Albertini et al., 2003).
These included GST M1, GST T1, CYP2E1 (5# promoter
region), CYP2E1 (intron 6), EH113, EH139, ADH2, and
ADH3. In addition, hydrolysis phenotypes were determined by
combinations of EH genotypes. As noted above, only the GST
genotypes appeared to influence metabolism in this study, that
FIG. 9. Associations between individual pyr-Val hemoglobin adduct
concentrations (ln[pmol/g]) and urine M2/(M1 þ M2) concentrations (ln[lg/l]).
TABLE 4




Control Monomer Polymerization All
M1 0.08 0.51* 0.28 0.52**
M2 0.19 0.35 0.19 0.47**
M2/(M1 þ M2) 0.30 0.23 0.06 0.34**
*p < 0.05, **p < 0.01.
FIG. 7. Associations between individual pyr-Val hemoglobin adduct
concentrations (ln[pmol/g]) and urine M1 concentrations (ln[lg/l]).
FIG. 8. Associations between individual pyr-Val hemoglobin adduct
concentrations (ln[pmol/g]) and urine M2 concentrations (ln[lg/l]).
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being in the ratio M2/(M1 þ M2) and its rate of change with
increasing BD exposure levels.
In the current study, none of the polymorphisms studied
showed a consistent genotype effect and formation of pyr-Val
across the three exposure groups (controls, monomer production
workers, polymerization workers) as indicted by a nonsignificant
main effect of genotype in two-way ANOVA. In addition, there
were no significant interactions between exposure group and
genotype. Regression of ln(pyr-Val) on ln(BD) and genotype
revealed no significant effects of genotype on the relationship
between pyr-Val and BD exposures (data not shown). Similarly,
analyses using ln(THB-Val) instead of ln(BD) as the in-
dependent exposure variable did not reveal any significant effect
of genotype on the relationship between pyr-Val and THB-Val.
Hydrolysis phenotypes determined by combinations of EH
genotypes had no effect on pyr-Val.
DISCUSSION
Protein adducts derived from BD have been widely used as
biomarkers of exposure and metabolic activation applying the
modified Edman degradation method (Törnqvist et al., 2002).
The formation of N-terminal valine adducts, HB-Val and THB-
Val, as biomarkers for EB and EB-diol formation, respectively,
demonstrated that adduct formation correlates with BD exposure
(Albertini et al., 2003; Boysen et al., 2007). Investigation of HB-
Val and THB-Val in mice and rats showed clear species
differences in BD metabolism, suggesting that metabolic
differences parallel the observed species differences in carcino-
genic susceptibility, with mice being most efficient in BD
oxidation and more susceptible than rats to BD-induced
carcinogenesis (Swenberg et al., 2001). In general, BD is
mainly (> 96%) metabolized via the BD-diol pathway in both
rodent species. Unfortunately, no in vivo data were available on
the formation of pyr-Val in either species until we reported the
presence of pyr-Val in mice and rats exposed to BD by
inhalation (Boysen et al., 2004) and more recently reported
a comprehensive exposure-response for pyr-Val in mice and rats
(Georgieva et al., 2010). Interestingly, mice form about 10- to
60-fold more pyr-Val than rats, a difference mirroring the tumor-
response data (IARC, 2008). Correlation of protein adducts with
mutation frequencies in the HPRT gene was strongest for pyr-
Val compared with correlations of MF with HB-Val or THB-Val
(Georgieva et al., 2010). This correlation analysis implies that
DEB is the ultimate mutagenic and carcinogenic metabolite in
rodents. Consequently, it is very important for accurate risk
assessment to determine whether humans form pyr-Val and at
what rate compared with mice and rats, which were used for
cancer bioassays. Therefore, globin samples from the previous
molecular epidemiology study of BD-exposed workers in the
Czech Republic were analyzed for the presence of pyr-Val. We
report herein for the first time the formation of pyr-Val in
occupationally exposed workers (Fig. 3). The same samples had
already been analyzed for HB-Val and THB-Val and several
other biomarkers of exposure and effect allowing multiple
comparisons (Albertini et al., 2003).
Surprisingly, 68 of the 83 (84%) samples had quantifiable
amounts of pyr-Val ranging from 0.02 to 0.86 pmol/g, and pyr-
Val was found in a majority of globin samples from
administration workers (control group), suggesting common
environmental exposures to BD. This finding was not expected
because pyr-Val had previously not been observed in control
mice or rats, and DEB is not known to be an endogenous
metabolite (Boysen et al., 2004; Georgieva et al., 2010).
Current ongoing analyses of additional human globins have
confirmed the presence of pyr-Val in subjects not known to be
exposed to BD (Swenberg et al., unpublished data). The source
of the background amounts of pyr-Val remains to be
determined.
Smokers and subjects exposed to secondhand smoke exhale
as much as 353 and 14.4 lg/m3 BD (0.16 and 0.0065 ppm BD,
respectively) intermittently during a day. Therefore, smoking
produces short-term exposures that are lower than the mean
average concentration at the workplace (Gordon et al., 2002) or
the maximum TWA BD concentration of 39.03 mg/m3 (17.7
ppm) observed in the present study. Environmental BD
exposures in the range of 1–4 ppb have been attributed to
auto exhaust, which in urban centers can contribute up to 68%
of all BD emissions and can reach peak exposures up to 10 ppb
(Dollard et al., 2001). Therefore, smoking (active or passive)
and auto exhaust in high traffic areas are probably the main
nonoccupational sources for BD exposure, followed by
TABLE 5








% Cells with aberrations 0.22 0.03 0.22 0.17
Breaks per cell 0.29 0.12 0.27 0.22*
Sister chromatid exchangesb 0.41 0.31 0.07 0.03
FISHc
Aberrant chromosomes 0.22 0.47* 0.11 0.04
Translocations 0.22 0.50* 0.16 0.06
Reciprocal translocations 0.31 0.46* 0.08 0.08
Cojunctions 0.20 0.45* 0.19 0.04
FGt/100 0.22 0.50* 0.16 0.06
aSamples from one monomer worker lost to analysis.
bSamples from seven monomer workers and three polymerization workers
lost to analysis.
cSamples from one control, one monomer, and one polymerization worker
lost to analysis.
*p < 0.05.
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emissions from coal, wood, oil, or waste burning (IARC,
2008). In the present study, however, there was no association
between smoking status and amounts of pyr-Val, suggesting
that in our population, environmental BD exposures, including
second hand smoke, may be more important than previously
estimated. The mean BD exposure of 10 ppb in the control
group was higher than reported for other regions, where
exposures range from 0.01 to 1 ppb (IARC, 2008). Whether
this high BD exposure in the control group is due to close
proximity to the BD monomer and polymerization plant or due
to regionally high environmental BD exposures because of
traffic or coal heating is unknown. How environmental BD
exposures, which were 30- or 3000-fold lower than the mean
occupational or short-term smoking related exposures, pro-
duced the observed amounts of pyr-Val remains to be
determined.
Overall, pyr-Val was significantly correlated with the
average BD exposure of individual workers demonstrating
that occupational BD exposure does lead to elevated formation
of DEB in humans (Fig. 4). This is the first study to
demonstrate elevated formation of DEB in occupationally
exposed workers. Even though pyr-Val did demonstrate the
formation of DEB in occupationally exposed workers, the
human response is very different from that of rats and mice.
Mice form ~100-fold greater amounts of DEB when exposed to
similar concentrations of BD and rats form ~10-fold greater
amounts than humans (Georgieva et al., 2010). These data
demonstrate less efficient formation of DEB in humans
compared with rodents exposed to similar BD concentrations
and suggest that humans may be less susceptible to BD-
induced mutagenesis and carcinogenesis than the test animals
used in cancer bioassays. We recently reported a comparative
analysis of all three adducts in mouse, rat, and human exposed
to similar BD concentrations (Swenberg et al., 2011).
Conversion of pyr-Val adducts into EB-equivalents in each
species suggest that in humans, DEB contributes significantly
less to mutagenic effects than in rodents. Rather, it appears that
EB-diol is the major metabolite in humans that is responsible
for most of the EB-equivalents in humans.
Biomarkers of effect, such as HPRT mutations and
chromosomal damage, did not show an exposure related
increase in BD workers. In contrast, mice exposed to BD have
clear increases in HPRT mutations at exposures of  6.25 ppm
BD, and rats show similar increases at exposures of  62.5
ppm (Georgieva et al., 2010). The amount of pyr-Val present
following 10 days of 6.25-ppm BD exposure to mice was 75.8
pmol/g globin, whereas rats exposed to 62.5 ppm BD had 47
pmol/g globin. In comparison the highest pyr-Val measurement
in this study was 0.86 pmol/g demonstrating that pyr-Val
formation is over 50-fold lower in occupationally exposed
humans than has been associated with mutagenesis in rodents.
More recent exposure assessments in the same plant showed
that current BD exposures are even lower (Albertini et al.,
2007), suggesting that current risk to BD-induced mutations
and cancers in the studied workers is low. As expected, pyr-Val
formation did not correlate with MF or VF when analyzing all
subjects or individual groups, although the number of
chromosome breaks correlated with amounts of pyr-Val when
all subjects were included. Thus the BD-exposure studied may
produce DEB that form significant amounts of pyr-Val and
chromosome breaks, but were insufficient to form permanent
mutations.
The individual differences of pyr-Val amounts within each
exposure group of 14-, 24-, and 25-fold for control, monomer,
and polymerization, respectively, was greater than the mean
difference between the groups of 1.8- and 2.4-fold between
control and the monomer workers and monomer and
polymerization workers, respectively. Such large variability
within the groups might be the reason why the mean amounts
of pyr-Val were only significantly different between the
polymerization workers and the control. Large individual
differences of biomarker measurements such as for pyr-Val and
relatively small difference between groups have been common
in biomarker research, driving the need for larger numbers of
subjects per group to obtain significant findings. However, the
application of pyr-Val as a predictive biomarker for human
cancer risk remains questionable because humans form so little,
compared with the other epoxide globin adducts.
On the other hand, analyses of multiple BD-derived protein
adducts are expected to give important information about BD
exposure and the rates of individual metabolic pathways. Such
knowledge might be more predictive for risk phenotypes than
individual biomarkers of exposure. Amounts of pyr-Val did
correlate with the amounts of HB-Val in the monomer and
polymerization workers. Controls and monomer workers formed
about two and three times more HB-Val than pyr-Val. In
contrast, polymerization workers formed much less (eightfold)
pyr-Val than HB-Val, suggesting significantly different rates of
conversion of EB to DEB in the polymerization workers
compared with the other two groups. The reason for these
relative differences in formation of the individual epoxides may
relate to saturation of the formation of pyr-Val. In rats, the
formation of pyr-Val reaches a plateau after exposures greater
than 442 mg/m3 (200 ppm) BD for 10 days (Georgieva et al.,
2010). In addition, the slope of pyr-Val formation is lower at
exposures greater than 3.32 mg/m3 (1.5 ppm) and 13.8 mg/m3
(6.25 ppm) BD in mice and rats, respectively (Georgieva et al.,
2010). Therefore, it is conceivable that formation of pyr-Val may
also saturate in humans, but at much lower exposures.
Unfortunately, the number of subjects in this study with
exposures > 3 mg/m3 (1.4 ppm) was too small to establish
a biphasic exposure-response in humans.
BD was mainly (99.6%) metabolized via the BD-diol
pathway, as estimated from the percentage of THB-Val to total
amounts of N-terminal valine adducts. HB-Val and pyr-Val
represented 0.26 and 0.12% of the total amounts of adducts in
the control and monomer workers, respectively. Interestingly,
this distribution changes significantly for the polymerization
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workers, where the relative formation of pyr-Val is twofold
lower, and formation of HB-Val is increased by 30% (Table 1),
whereas the fraction of THB-Val remains unchanged. These
changes in adduct distribution are consistent with reduced
formation of pyr-Val and subsequent accumulation of HB-Val.
Moreover, the ratios of HB-Val/pyr-Val (mean 10.85 ± 11.54 vs.
4.12 ± 3.9, p < 0.001) were significantly different in the polymer
workers compared with monomer workers. The exposures in the
polymerization plant contained several additional compounds
known to alter metabolic rates due to inhibition, induction, or
activation. For example, coexposures to compounds like benzene
and styrene are likely to compete with BD for activation by P450
2e1 (Hartman et al., submitted). The mean styrene exposure was
significantly higher (14-fold) in the polymerization workers
(2.12 mg/m3) compared with controls (0.12 mg/m3) and
monomer workers (0.15 mg/m3) (Albertini et al., 2003).
Adjustment for styrene coexposures did not improve the
correlation analyses (data not shown), suggesting that additional
confounding factors (e.g., benzene, toluene, and 1-butanol) are
present in the polymer exposure group. Conclusively, it appears
that the metabolism of BD to epoxides leading to protein adducts
is significantly different in polymerization workers, compared
with the control group and monomer workers.
In addition to being further oxidized to DEB, EB is
metabolized to the N-acetyl cysteine conjugates (NAC) and
excreted in the urine. The main pathway is hydrolysis by EH to
BD-diol and subsequent conjugation to NAC, a GST-catalyzed
reaction-producing M1. EB itself is a substrate for GST and
can be directly conjugated with NAC to form M2. Conse-
quently, the M1/(M1 þ M2) ratio is an indicator for the relative
rate of EB hydrolysis by EH or direct conjugation of EB with
NAC. In the current study, > 98% of EB is excreted as the M1
metabolite (Albertini et al., 2003), a finding that is in
agreement with hemoglobin adducts (discussed above),
suggesting that > 99.6% of BD is metabolized via the BD-
diol pathway. Investigating the ratio of M2/(M1 þ M2)
demonstrates that the relative formation of M2 increases with
BD exposures, suggesting activation of the GST mediated
direct conjugation pathway. As would be expected, analysis of
M2/(M1 þ M2) ratio by genotypes revealed that the increased
activation of the direct conjugation pathway is stronger in the
GST positive compared with both GST M1 and GST T1
negative genotypes. This was significant for GST M1
confirming the importance of GST M1 in detoxification of
BD metabolites. The relative increase in M2 metabolite in the
polymerization workers is an indirect indication for accumu-
lation of EB and consistent with higher percentages of HB-Val
compared with pyr-Val in the polymerization workers
compared with controls and monomer workers (Table 1).
Together, hemoglobin adducts and urinary metabolites show
the dominance of the BD-diol pathway for BD metabolism.
Both sets of biomarkers provide evidence for a difference in
BD metabolism between the polymerization workers and both
the control subjects and the monomer workers. The individual
differences for the urinary biomarkers were greater than the
individual differences of the hemoglobin adducts. This
demonstrates that hemoglobin adducts are less affected by
daily exposures and dilution effects than urinary metabolites.
In summary, we report herein the presence of DEB, the most
mutagenic and carcinogenic BD-derived metabolite, in BD-
exposed workers. Formation of DEB in humans, as measured
by pyr-Val, is much lower compared with mice and rats
exposed similarly. Occupational exposures in a polymerization
facility lead to significant increases in pyr-Val over controls
and monomer plant workers. Correlation analyses with
previously analyzed HB-Val, THB-Val, M1, and M2 further
suggest that the metabolism of EB to DEB is significantly
different in polymerization workers compared with monomer
workers or control subjects. Whether pyr-Val formation
saturates, GST activity increases with increased BD exposures
or if coexposures to other compounds in the polymerization
plant, such as benzene and styrene, alter BD metabolism could
not be determined. The amounts of pyr-Val formed in this
study were not associated with increases in MF or VF in the
HPRT gene, although pyr-Val formation correlated with
increased chromosome breaks. Low amounts of pyr-Val were
also present in control subjects, suggesting formation from
environmental exposures to BD.
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